Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that is most
commonly treated with combination chemo-immunotherapy at diagnosis because of the …

Chimeric antigen receptor-modified (CAR) T-cell therapy targeting CD19 has revolutionized
the treatment of relapsed or refractory B-cell lymphomas. Based on unprecedented …

Purpose Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell …

Summary Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …

Background Patients with relapsed or refractory mantle-cell lymphoma who have disease
progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy …

PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase
inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent …

Executive Summary Clinical Cancer Advances 2021: ASCO's Report on Progress Against
Cancer highlights the most important clinical research advances of the past year and …

Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-
Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of …

Introduction: The therapeutic options for mantle cell lymphoma (MCL) include traditional
chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the …

Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all
NHLs and characterized by overexpression of cyclin D1. The last decade has seen the …